This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is GoodRx (GDRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how GoodRx Holdings, Inc. (GDRX) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.
ELV vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
ELV or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
Wall Street Analysts Predict a 29.1% Upside in GoodRx Holdings, Inc. (GDRX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 29.1% upside potential for GoodRx Holdings, Inc. (GDRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Encompass Health (EHC), Piedmont to Build Loganville Facility
by Zacks Equity Research
Encompass Health (EHC) partners with Piedmont to construct a 40-bed inpatient rehabilitation hospital in Georgia to better serve the rehabilitative care needs of the state and solidify its footprint.
ELV or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
Can GoodRx Holdings, Inc. (GDRX) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
GoodRx Holdings, Inc. (GDRX) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does GoodRx Holdings, Inc. (GDRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
GoodRx Holdings, Inc. (GDRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for GoodRx Holdings, Inc. (GDRX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
GoodRx Holdings, Inc. (GDRX) Matches Q4 Earnings Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 0% and 0.54%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Agiliti (AGTI) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Agiliti (AGTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What to Look for in Crescent Point's (CPG) Q4 Earnings?
by Zacks Equity Research
Lower price realizations and an upward cost trajectory are likely to have dented Crescent Point Energy's (CPG) fourth-quarter results.
Countdown to GoodRx Holdings, Inc. (GDRX) Q4 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for GoodRx Holdings, Inc. (GDRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
What Will Global Partners' (GLP) Q4 Earnings Unveil?
by Zacks Equity Research
Global Partners LP (GLP) beat the Zacks Consensus Estimate for earnings in two of the last four quarters and missed in the other two.
GoodRx Holdings, Inc. (GDRX) Reports Next Week: What Awaits?
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Medtronic (MDT) in Q3 Earnings?
by Zacks Equity Research
Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal third-quarter performance.
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the fourth quarter.
Labcorp (LH) to Report Q4 Earnings: What's in the Cards? (Revised)
by Zacks Equity Research
Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.
Can Tenet's (THC) Q4 Earnings Beat on Rising Patient Admissions?
by Zacks Equity Research
Tenet's (THC) fourth-quarter results are likely to reflect higher Ambulatory Care operating revenues and supply costs.
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) fiscal second-quarter results are likely to be driven by its non-COVID non-Sarepta Biologics business.
Encompass Health (EHC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Encompass Health's (EHC) fourth-quarter results are likely to reflect pricing increases and growing volumes.
Labcorp (LH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.
Will High Medical Costs Affect Centene's (CNC) Q4 Earnings?
by Zacks Equity Research
Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and overall memberships.
How Much Upside is Left in GoodRx Holdings, Inc. (GDRX)? Wall Street Analysts Think 27.83%
by Zacks Equity Research
The consensus price target hints at a 27.8% upside potential for GoodRx Holdings, Inc. (GDRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Cigna (CI) to Report Q4 Earnings: Can Rising Expenses Hurt?
by Zacks Equity Research
Cigna's (CI) fourth-quarter results are likely to reflect growth in Evernorth revenues and customer base.